FI119176B - Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo - Google Patents

Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo Download PDF

Info

Publication number: FI119176B
Authority: FI; Finland
Prior art keywords: adenovirus; combination according; gene; pharmaceutical combination; recombinant dna
Prior art date: 1995-02-14

Application number

FI973323A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI973323A0 (fi

FI973323L (fi

Inventor

Michel Perricaudet

Hedi Haddada

Jean-Francois Bach

Lucienne Chatenoud

Martin Lee

Michelle Webb

Original Assignee

Inst Nat Sante Rech Med

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-14

Filing date

1997-08-13

Publication date

2008-08-29

1997-08-13 Application filed by Inst Nat Sante Rech Med, Rhone Poulenc Rorer Sa filed Critical Inst Nat Sante Rech Med

1997-08-13 Publication of FI973323A0 publication Critical patent/FI973323A0/fi

1997-08-13 Publication of FI973323L publication Critical patent/FI973323L/fi

2008-08-29 Application granted granted Critical

2008-08-29 Publication of FI119176B publication Critical patent/FI119176B/fi

Links

238000001727 in vivo Methods 0.000 title claims abstract description 12
238000001890 transfection Methods 0.000 title claims abstract description 6
230000014509 gene expression Effects 0.000 title claims description 40
239000000890 drug combination Substances 0.000 title claims description 10
230000003721 exogen phase Effects 0.000 title description 2
108090000623 proteins and genes Proteins 0.000 claims abstract description 146
241000701161 unidentified adenovirus Species 0.000 claims abstract description 124
108020004511 Recombinant DNA Proteins 0.000 claims abstract description 53
230000001225 therapeutic effect Effects 0.000 claims abstract description 31
239000003018 immunosuppressive agent Substances 0.000 claims abstract description 19
230000002480 immunoprotective effect Effects 0.000 claims abstract description 14
102000004169 proteins and genes Human genes 0.000 claims description 30
230000002950 deficient Effects 0.000 claims description 24
102000004127 Cytokines Human genes 0.000 claims description 18
108090000695 Cytokines Proteins 0.000 claims description 18
241001465754 Metazoa Species 0.000 claims description 18
230000000694 effects Effects 0.000 claims description 18
238000002347 injection Methods 0.000 claims description 16
239000007924 injection Substances 0.000 claims description 16
241000282414 Homo sapiens Species 0.000 claims description 13
102100021244 Integral membrane protein GPR180 Human genes 0.000 claims description 10
108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 10
238000013518 transcription Methods 0.000 claims description 8
230000035897 transcription Effects 0.000 claims description 8
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 6
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
108010036949 Cyclosporine Proteins 0.000 claims description 5
229960001265 ciclosporin Drugs 0.000 claims description 5
229930182912 cyclosporin Natural products 0.000 claims description 5
241000282472 Canis lupus familiaris Species 0.000 claims description 4
229930105110 Cyclosporin A Natural products 0.000 claims description 4
241000699670 Mus sp. Species 0.000 claims description 4
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 4
229960002170 azathioprine Drugs 0.000 claims description 4
210000002865 immune cell Anatomy 0.000 claims description 4
241000283690 Bos taurus Species 0.000 claims description 3
241000282693 Cercopithecidae Species 0.000 claims description 3
230000030741 antigen processing and presentation Effects 0.000 claims description 3
239000003246 corticosteroid Substances 0.000 claims description 3
229960001334 corticosteroids Drugs 0.000 claims description 3
230000006378 damage Effects 0.000 claims description 3
108700022375 Human herpesvirus 1 VP23 Proteins 0.000 claims description 2
230000000415 inactivating effect Effects 0.000 claims description 2
241001529453 unidentified herpesvirus Species 0.000 claims description 2
241000282887 Suidae Species 0.000 claims 2
230000001506 immunosuppresive effect Effects 0.000 claims 2
241000283903 Ovis aries Species 0.000 claims 1
229940125721 immunosuppressive agent Drugs 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 80
241000700605 Viruses Species 0.000 description 41
108020004414 DNA Proteins 0.000 description 35
239000013598 vector Substances 0.000 description 33
239000013612 plasmid Substances 0.000 description 20
239000012634 fragment Substances 0.000 description 17
241001135569 Human adenovirus 5 Species 0.000 description 16
239000000047 product Substances 0.000 description 15
238000000034 method Methods 0.000 description 14
238000010276 construction Methods 0.000 description 11
238000012217 deletion Methods 0.000 description 11
230000037430 deletion Effects 0.000 description 11
230000006870 function Effects 0.000 description 11
210000000987 immune system Anatomy 0.000 description 11
241000714474 Rous sarcoma virus Species 0.000 description 10
230000028993 immune response Effects 0.000 description 9
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
230000001413 cellular effect Effects 0.000 description 7
230000004927 fusion Effects 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
102100040247 Tumor necrosis factor Human genes 0.000 description 6
108010005774 beta-Galactosidase Proteins 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
238000001415 gene therapy Methods 0.000 description 6
230000007170 pathology Effects 0.000 description 6
102100038909 Caveolin-2 Human genes 0.000 description 5
101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 5
102000005936 beta-Galactosidase Human genes 0.000 description 5
230000009089 cytolysis Effects 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
230000010076 replication Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
241000598171 Human adenovirus sp. Species 0.000 description 4
102000000589 Interleukin-1 Human genes 0.000 description 4
108010002352 Interleukin-1 Proteins 0.000 description 4
108020005202 Viral DNA Proteins 0.000 description 4
230000008030 elimination Effects 0.000 description 4
238000003379 elimination reaction Methods 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
210000005260 human cell Anatomy 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
230000009467 reduction Effects 0.000 description 4
210000003660 reticulum Anatomy 0.000 description 4
238000012216 screening Methods 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
210000004989 spleen cell Anatomy 0.000 description 4
230000001629 suppression Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
101150067954 B15R gene Proteins 0.000 description 3
102100035888 Caveolin-1 Human genes 0.000 description 3
102000004594 DNA Polymerase I Human genes 0.000 description 3
108010017826 DNA Polymerase I Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
101000715467 Homo sapiens Caveolin-1 Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
101150039910 UL18 gene Proteins 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
229960003444 immunosuppressant agent Drugs 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
238000001823 molecular biology technique Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
101150067964 BcRF1 gene Proteins 0.000 description 2
241000701157 Canine mastadenovirus A Species 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
101150029662 E1 gene Proteins 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
101150044134 US28 gene Proteins 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000008260 defense mechanism Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000009144 enzymatic modification Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000001861 immunosuppressant effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000035990 intercellular signaling Effects 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
210000000207 lymphocyte subset Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000008520 organization Effects 0.000 description 2
102000005162 pleiotrophin Human genes 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000011664 signaling Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000014616 translation Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
101150072531 10 gene Proteins 0.000 description 1
PXKSAXUKRMRORY-ZWKOTPCHSA-N 2-(3,4-dichlorophenyl)-n-[(1s,2r)-2-(2,5-dihydropyrrol-1-yl)cyclohexyl]-n-methylacetamide Chemical compound N1([C@@H]2CCCC[C@@H]2N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CC=CC1 PXKSAXUKRMRORY-ZWKOTPCHSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
101150039990 B13R gene Proteins 0.000 description 1
101150023320 B16R gene Proteins 0.000 description 1
101150006352 B18R gene Proteins 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
108010021064 CTLA-4 Antigen Proteins 0.000 description 1
229940045513 CTLA4 antagonist Drugs 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
101100232885 Cowpox virus (strain Brighton Red) CPXV209 gene Proteins 0.000 description 1
102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 1
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000001039 Dystrophin Human genes 0.000 description 1
108010069091 Dystrophin Proteins 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
102000004038 Glia Maturation Factor Human genes 0.000 description 1
108090000495 Glia Maturation Factor Proteins 0.000 description 1
206010048748 Graft loss Diseases 0.000 description 1
101710155188 Hexon-interlacing protein Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 description 1
101900102284 Human herpesvirus 1 ICP47 protein Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000049772 Interleukin-16 Human genes 0.000 description 1
101800003050 Interleukin-16 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
108700005092 MHC Class II Genes Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241000701168 Murine adenovirus 1 Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
101100007739 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) crmA gene Proteins 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
101100091964 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cyt-5 gene Proteins 0.000 description 1
108090000742 Neurotrophin 3 Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
241000188845 Porcine adenovirus Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102100032889 Sortilin Human genes 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 description 1
102100028748 Transportin-1 Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
101100004091 Vaccinia virus (strain Copenhagen) B15R gene Proteins 0.000 description 1
101100316831 Vaccinia virus (strain Copenhagen) B18R gene Proteins 0.000 description 1
101100340726 Vaccinia virus (strain Western Reserve) VACWR197 gene Proteins 0.000 description 1
101100004099 Vaccinia virus (strain Western Reserve) VACWR200 gene Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
241000701792 avian adenovirus Species 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
239000004106 carminic acid Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
101150067246 crmA gene Proteins 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000005868 electrolysis reaction Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
230000007108 local immune response Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000035772 mutation Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000004224 protection Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000006884 silylation reaction Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
-1 α-1ΑΤ Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Virology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FI973323A 1995-02-14 1997-08-13 Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo FI119176B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
FR9501662A FR2730411B1 (fr)	1995-02-14	1995-02-14	Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
FR9501662		1995-02-14
FR9600218		1996-01-10
PCT/FR1996/000218 WO1996025177A1 (fr)	1995-02-14	1996-02-12	Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (3)

Publication Number	Publication Date
FI973323A0 FI973323A0 (fi)	1997-08-13
FI973323L FI973323L (fi)	1997-08-13
FI119176B true FI119176B (fi)	2008-08-29

Family

ID=9476106

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI973323A FI119176B (fi)	1995-02-14	1997-08-13	Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo

Country Status (23)

Country	Link
US (2)	US20030004091A1 (hu)
EP (1)	EP0809516B1 (hu)
JP (1)	JPH11500430A (hu)
KR (1)	KR100402540B1 (hu)
AT (1)	ATE204481T1 (hu)
AU (1)	AU717218B2 (hu)
BR (1)	BR9607310A (hu)
CA (1)	CA2211039C (hu)
CZ (1)	CZ258197A3 (hu)
DE (1)	DE69614668T2 (hu)
DK (1)	DK0809516T3 (hu)
ES (1)	ES2163612T3 (hu)
FI (1)	FI119176B (hu)
FR (1)	FR2730411B1 (hu)
GR (1)	GR3036438T3 (hu)
HU (1)	HU222991B1 (hu)
IL (1)	IL117116A0 (hu)
MX (1)	MX9706017A (hu)
NO (1)	NO320072B1 (hu)
PT (1)	PT809516E (hu)
SK (1)	SK282235B6 (hu)
WO (1)	WO1996025177A1 (hu)
ZA (1)	ZA961161B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6451571B1 (en)	1994-05-02	2002-09-17	University Of Washington	Thymidine kinase mutants
WO1998008539A1 (en) *	1996-08-26	1998-03-05	Chiron Corporation	Postinfection human immunodeficiency virus (hiv) vaccination therapy
US6525029B1 (en)	1997-10-30	2003-02-25	Cornell Research Foundation, Inc.	Method of inhibiting and immune response to a recombinant vector
WO2000039304A2 (en)	1998-12-31	2000-07-06	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1141313A2 (en)	1998-12-31	2001-10-10	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
WO2000074688A1 (en) *	1999-06-08	2000-12-14	The Children's Hospital Of Philadelphia	Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
FR2799472B1 (fr) *	1999-10-07	2004-07-16	Aventis Pharma Sa	Preparation d'adenovirus recombinants et de banques adenovirales
BR0111158A (pt)	2000-05-12	2004-04-06	Genzyme Corp	Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
US7211659B2 (en)	2001-07-05	2007-05-01	Chiron Corporation	Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en)	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7569217B2 (en) *	2001-09-24	2009-08-04	University Of Saskatchewan	Porcine adenovirus E1 and E4 regions
EP1432447A2 (en) *	2001-09-27	2004-06-30	The Board Of Regents, The University Of Texas System	Combined compositions and methods for tumor vasculature coagulation and treatment
ES2363914T3 (es) *	2002-11-21	2011-08-19	Genzyme Corporation	Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
AU2003291143A1 (en) *	2002-11-21	2004-06-18	Genzyme Corporation	Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
EP1725254A4 (en) *	2004-02-04	2008-02-13	Univ Columbia	ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY
WO2008013918A2 (en) *	2006-07-26	2008-01-31	Myelin Repair Foundation, Inc.	Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994016065A1 (en) *	1992-12-31	1994-07-21	Exemplar Corporation	Producing cells for transplantation to reduce host rejection and resulting cells
WO1994016080A1 (en) *	1993-01-08	1994-07-21	Exemplar Corporation	An in vitro/in vivo method for identifying anti-neoplastic drugs
FR2705686B1 (fr) *	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) *	1995-02-24	1999-02-16	The Trustees Of The University Of Pennsylvania	Method of reducing an immune response to a recombinant adenovirus

1995
- 1995-02-14 FR FR9501662A patent/FR2730411B1/fr not_active Expired - Fee Related
1996
- 1996-02-12 ES ES96903080T patent/ES2163612T3/es not_active Expired - Lifetime
- 1996-02-12 DK DK96903080T patent/DK0809516T3/da active
- 1996-02-12 JP JP8524707A patent/JPH11500430A/ja not_active Ceased
- 1996-02-12 IL IL11711696A patent/IL117116A0/xx unknown
- 1996-02-12 AT AT96903080T patent/ATE204481T1/de active
- 1996-02-12 BR BR9607310A patent/BR9607310A/pt not_active Application Discontinuation
- 1996-02-12 AU AU47238/96A patent/AU717218B2/en not_active Ceased
- 1996-02-12 SK SK1108-97A patent/SK282235B6/sk not_active IP Right Cessation
- 1996-02-12 US US08/894,246 patent/US20030004091A1/en not_active Abandoned
- 1996-02-12 HU HU9800635A patent/HU222991B1/hu not_active IP Right Cessation
- 1996-02-12 WO PCT/FR1996/000218 patent/WO1996025177A1/fr not_active Ceased
- 1996-02-12 CZ CZ972581A patent/CZ258197A3/cs unknown
- 1996-02-12 DE DE69614668T patent/DE69614668T2/de not_active Expired - Lifetime
- 1996-02-12 PT PT96903080T patent/PT809516E/pt unknown
- 1996-02-12 CA CA2211039A patent/CA2211039C/fr not_active Expired - Fee Related
- 1996-02-12 EP EP96903080A patent/EP0809516B1/fr not_active Expired - Lifetime
- 1996-02-12 KR KR1019970705594A patent/KR100402540B1/ko not_active Expired - Fee Related
- 1996-02-12 MX MX9706017A patent/MX9706017A/es unknown
- 1996-02-13 ZA ZA961161A patent/ZA961161B/xx unknown
1997
- 1997-08-13 NO NO19973724A patent/NO320072B1/no not_active IP Right Cessation
- 1997-08-13 FI FI973323A patent/FI119176B/fi not_active IP Right Cessation
2001
- 2001-08-23 GR GR20010400947T patent/GR3036438T3/el unknown
2004
- 2004-04-14 US US10/823,682 patent/US20040265276A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO973724D0 (no)	1997-08-13
CA2211039C (fr)	2011-12-06
ES2163612T3 (es)	2002-02-01
HU222991B1 (hu)	2004-01-28
EP0809516A1 (fr)	1997-12-03
US20040265276A1 (en)	2004-12-30
CZ258197A3 (en)	1997-11-12
FI973323A0 (fi)	1997-08-13
CA2211039A1 (fr)	1996-08-22
SK110897A3 (en)	1998-01-14
EP0809516B1 (fr)	2001-08-22
NO320072B1 (no)	2005-10-17
BR9607310A (pt)	1997-11-25
ATE204481T1 (de)	2001-09-15
US20030004091A1 (en)	2003-01-02
HUP9800635A3 (en)	2000-12-28
AU4723896A (en)	1996-09-04
MX9706017A (es)	1997-11-29
FR2730411B1 (fr)	1997-03-28
DE69614668D1 (de)	2001-09-27
KR19980702199A (ko)	1998-07-15
PT809516E (pt)	2002-02-28
GR3036438T3 (en)	2001-11-30
NO973724L (no)	1997-08-13
IL117116A0 (en)	1996-06-18
DK0809516T3 (da)	2001-12-17
ZA961161B (en)	1996-08-07
HUP9800635A2 (hu)	1998-07-28
WO1996025177A1 (fr)	1996-08-22
FR2730411A1 (fr)	1996-08-14
FI973323L (fi)	1997-08-13
SK282235B6 (sk)	2001-12-03
JPH11500430A (ja)	1999-01-12
DE69614668T2 (de)	2002-06-27
AU717218B2 (en)	2000-03-23
KR100402540B1 (ko)	2004-05-07

Publication	Publication Date	Title
EP1749098B1 (en)	2010-12-15	Chimeric adenoviruses for use in cancer treatment
KR100356615B1 (ko)	2003-04-03	결함아데노바이러스벡터및유전자치료에서그의사용
CN106471125B (zh)	2021-04-06	包括白蛋白结合部分的腺病毒
JP3816952B2 (ja)	2006-08-30	治療遺伝子と免疫保護遺伝子とを含む欠陥アデノウイルス
FI119176B (fi)	2008-08-29	Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo
CZ302895A3 (en)	1996-02-14	The use of recombinant adenovirus of animal origin for preparing a pharmaceutical preparation
FR2707664A1 (fr)	1995-01-20	Vecteurs viraux et utilisation en thérapie génique.
FR2729674A1 (fr)	1996-07-26	Cellules pour la production d'adenovirus recombinants

Legal Events

Date	Code	Title	Description
2008-08-29	FG	Patent granted	Ref document number: 119176 Country of ref document: FI
2014-09-18	MM	Patent lapsed

Date

Code

Title

Description